Back to Search
GLORIA WISEMAN, M.D.
M.D.
Neonatal-Perinatal Medicine Physician
NPI: 1821162801Individual
Specialties, Licenses & Credentials
Neonatal-Perinatal Medicine PhysicianPrimary
Pediatrics — Neonatal-Perinatal Medicine
Code: 2080N0001X
151187(NY)MA47936(NJ)
Research & Publications (20)
Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.
PMID 19029411·J Clin Oncol·2009
8-other
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
PMID 19255322·J Clin Oncol·2009
3-trial
Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.
PMID 18391991·Bone Marrow Transplant·2008
6-review
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
PMID 18501102·Clin Lymphoma Myeloma·2008
8-other
18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.
PMID 18630999·Thyroid·2008
8-other
Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
PMID 17413571·Clin Nucl Med·2007
5-case
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
PMID 17414887·Nucl Med Commun·2007
8-other
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland.
PMID 17504869·J Nucl Med·2007
8-other
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
PMID 17705349·Cancer Immun·2007
3-trial
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
PMID 17875803·Clin Cancer Res·2007
3-trial
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
PMID 17979571·Cancer Biother Radiopharm·2007
1-meta
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
PMID 18021468·Clin Lymphoma Myeloma·2007
3-trial
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
PMID 17380530·Cancer·2007
3-trial
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
PMID 17242397·J Clin Oncol·2007
6-review
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
PMID 17901765·Nucl Med Commun·2007
8-other
Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism.
PMID 16470331·World J Surg·2006
8-other
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
PMID 16690521·Leuk Lymphoma·2006
8-other
Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.
PMID 16770786·Cancer·2006
8-other
Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
PMID 16966270·Leuk Lymphoma·2006
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 570 FORT WASHINGTON AVE
NEW YORK, NY 10033 - Phone
- (212) 795-3293
Quick Facts
- NPI
- 1821162801
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile